ANTI-SCARRING 

 GENE THERAPY

The future is here

cell3.png

Tcellexa ECHNOLOGY

CELLEXA  GENE THERAPY

Cellastra is piondering  

I'm a paragraph. Click here to add your own text and edit me. It's easy.

CELLEXA is a proprietary gene vector suitable for human use

Applied in the wound CELLEXA delivers the genetic code for expression and production of anti scarring peptides at the site of injury

CLX-003

CLX-003 is a formulation for injection after after back surgery (spinal laminectomy) or for prevention of intrabdominal adhesions after abdominal or gynecological surgery.

HOW DOES IT WORK?

  • CELLLEXA is a formulation of an effective transport vehicle  (viral vector)

  • Programmed with the genetic code for a  lactoferrin derived anti-scarring peptide. 

  • Applied on top of he skin or by injection  CELLEXA  delivers the code  to the targeted cells.

  • IEnables  continuous production  of anti-scarring peptides  in the  cells of the wound area for many weeks or months.

 

THE PEPTIDE DISRUPTS ROOT CAUSES OF SCARRING

CELLEXA (CLX-001)

CLX-001 is gene therapy to prevent  scarring after burn injury..

 

Applied topically by spray or ointment suitable for larger body surface area.  

Hypertrophic Scar.jpg

CLX-002

CXL-002 for prevention of dermal scarring after surgery. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challening areas such as the face, mammoplasty or after C-section..

Portfolio:

 1. CONTROLS INFLAMMATION

 inflammation promotes severe scarring

 2. STIMULATES FIBRINOLYSIS

  Bottom:  Blocked fibrinolysis promotes scarring. 

  Top: Reduced blocking increases fibrinolysis and scar resolution

3. FIGHTS  INFECTION

 infections cause inflammation which increases scar formation

388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com